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A B S T R A C T
Ischemic stroke is the main cause of disability and mortality worldwide. Apoptosis and inﬂammation have an
important role in ischemic brain injury. Mesenchymal stem cells (MSCs) have protective eﬀects on stroke
treatment due to anti-inﬂammatory properties. The inhibition of the C-Jun N-terminal kinase (JNK) pathway
may be one of the molecular mechanisms of the neuroprotective eﬀect of MSCs in ischemic brain injury.
Twenty-eight male Wistar rats were divided randomly into 3 groups. Except the sham group, others subjected
to transient middle cerebral artery occlusion (tMCAO). Bone marrow MSCs or saline were injected 3 h after
tMCAO. Sensorimotor behavioral tests were performed 24 and 72 h after ischemia and reperfusion (I/R). The
rats were sacriﬁced 72 h after I/R and infarct volume was measured by TTC staining. The number of apoptotic
neurons and astrocytes in the peri-infarct area was assessed by TUNEL assay. The morphology of cells was
checked by Nissl staining, and the expression of p-JNK was detected by immunohistochemistry and Western blot.
Behavioral scores were improved and infarct volume was reduced by MSCs 24 h and 72 h after tMCAO.
TUNEL assay showed that neuronal apoptosis and astroglial activity in the penumbra region were reduced by
MSCs. Also, Nissl staining showed lower neuronal apoptosis in BMSCs-treated rats compared to controls. JNK
phosphorylation which was profoundly induced by ischemia was signiﬁcantly decreased after MSCs treatment.
We concluded that anti-apoptotic and anti-inﬂammatory eﬀects of MSCs therapy after brain ischemia may be
associated with the down-regulation of p-JNK.
1. Introduction
Ischemic stroke is a major cause of long-term disability and mor-
tality, worldwide [1]. This crippling event result from a sudden drop in
brain blood ﬂow by an embolus or a thrombus and accounts for ap-
proximately 87% of all strokes [2]. Immediately after ischemic stroke, a
cascade of molecular events including excitotoxicity, increased levels of
intracellular calcium, oxidative stress and inﬂammation is initiated that
ultimately leads to apoptotic or necrotic neuronal cells death [3]. The
inﬂammatory process is characterized by the activation of resident
immune cells such as microglia and astrocytes, increasing vascular
permeability, reducing the integrity of the blood-brain barrier and in-
ﬁltration of peripheral immune cells including neutrophils, macro-
phages and T lymphocyte into the injured brain area. [4]. The inhibi-
tion of brain inﬂammation reduces infarct size and improves
neurological function [5,6]. The blockade of apoptosis attenuates cer-
ebral ischemic injury [7]. The primary goal of neuroprotective inter-
ventions is the protection of neurons in the surrounding area of the
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ischemic region [8]. There are a lot of studies about the pathophy-
siology, etiology, and treatment of ischemic stroke [9–11], but the
range of therapeutic interventions has remained very limited [12].
Currently, tissue plasminogen activator (tPA) is the only approved
pharmacological intervention with signiﬁcant beneﬁts in acute is-
chemic stroke. However, it is only eﬀective in the ﬁrst 4.5 h after the
onset of the brain ischemia [13].
Cell therapy is known as a promising strategy in the treatment of
many diseases, including. Stroke [14–16]. Mesenchymal stem cells
(MSCs) are among the cells that are widely considered for their char-
acteristics such as availability, rapidly expandable, and lack of ethical
and immunological problems in allogeneic transplantation [17]. Sev-
eral studies have shown the beneﬁcial eﬀects of MSCs transplantation in
the treatment of cerebral ischemic stroke [18,19]. The mechanisms
involved in MSCs–mediated therapeutic eﬀects in cerebral ischemia are
the ability to migrate to injured tissues, trans-diﬀerentiation into the
neural lineage, and the production of trophic factors and cytokines by
MSCs [20] suggesting the importance of paracrine signaling by MSCs
[21,22]. Recent research has indicated that the transplantation of bone
marrow mesenchymal stem cells (BMSCs) reduces the infarct size and
improves functional outcome following a brain stroke. Despite the
protective eﬀects, the exact molecular mechanisms are unknown.
Modulation of the immune system and reduction of the inﬂammatory
response by MSCs prevents secondary damage after stroke. Also,
apoptosis of neural cells after ischemic stroke can be suppressed by
these cells [23–25].
The c-Jun N-terminal kinase (JNK) cascade, also known as the
stress-activated signaling pathway, is a mitogen-activated protein ki-
nase (MAPK) that is activated in response to a wide variety of stresses,
including pro-inﬂammatory cytokines such as TNF-α [26], interleukin
1-beta [27] and many forms of environmental stress [28]. The activa-
tion of JNK leads to cell death via inﬂammation and apoptosis in many
cell types [29]. Studies revealed that activation of JNK is a major factor
in neuronal apoptosis triggered by focal and global ischemia [30].
Therefore, JNK signaling might have a role in the regulation of brain
inﬂammation which is followed by brain I/R injury progression
[30–32]. It was reported that inhibition of JNK activation may be
neuroprotective by suppression of inﬂammation in glial cells or apop-
tosis in neurons or both [33].
In this study, we examined the neuroprotective eﬀects of BMSCs
transplantation against cerebral I/R injury in a rat model of focal
ischemia. We also investigated the possible role of the JNK signaling
pathway for MSCs eﬀects.
2. Materials and methods
2.1. Animals and experimental groups
Adult male Wister rats weighing 230–280 g (8–10 weeks old) were
maintained in a 12 h light/dark cycle at the temperature (21 ± 2) °C
and allowed free access to food and water. All experimental protocols
were approved by the Kashan University of Medical Sciences Ethical
Committee by letter No. 3303, Date: 24.9.2014 and were carried out in
accordance with the Directive 2010/63/EU on the protection of animals
used for Scientiﬁc Purposes. A total of 28 rats were used in this study.
Animals were randomly divided into 3 groups: 1. Sham-operated group
(N=8), 2. Vehicle-treated I/R group or saline group (N=10) and 3.
BMSCs-treated I/R group or MSCs group (N=10). Rats received a
single injection of MSCs 3 h after tMCAO via the tail vein and were
sacriﬁced 72 h after I/R. The vehicle-treated group received an equal
volume of saline in the same manner of MSCs treatment.
2.2. Induction of transient focal cerebral ischemia
Transient focal cerebral ischemia was conducted with the use of the
intraluminal ﬁlament technique as described previously [34,35] with
some minor modiﬁcations. Brieﬂy, the rats were anesthetized by 3%
isoﬂurane (Baxter, USA) and maintained with 2% in an oxygen/air
mixture using isoﬂurane vaporizer (Eickemeiyer, Germany). During the
experiment, body temperature was kept at 37.0 ± 0.5 °C using a
heating pad (NARCO Bio-systems, USA). Laser Doppler ﬂowmetry
(Moor Instruments, U.K) was used to assure a successful occlusion and
reperfusion of the middle cerebral artery (MCA). Laser–Doppler mea-
suring sensors (P10d) were positioned and ﬁxed on both hemisphere of
skull surface, 1–2mm posterior and 4–5mm lateral to the bregma in
MCA territory for detecting cerebral blood ﬂow (CBF). A midline skin
incision in the neck was performed. The left common carotid artery
(CCA) was exposed and the vagus nerve was protected. Then silicon-
coated monoﬁlament (Doccol, USA) was gently inserted into the lumen
of CCA and forwarded to the internal carotid artery (ICA). When about
22mm of ﬁlament entered into the arteries, a signiﬁcant drop (> 60%)
occurred in CBF. At.this time, the entrance to the MCA was blocked.
The ﬁlament was ﬁxed for 60min and CBF was monitored at intervals
every 10min. After 1 h of occlusion, the ﬁlament was pulled out and
CCA was blocked, but the MCA was reperfused from Willis loop and
blood ﬂow was returned to the near of initial CBF. Then, the incision
was closed and rats were killed 72 h after reperfusion for histological
analysis and TTC staining. Sham-operated animals were subjected to
the same anesthesia and surgical procedures but the catheter was not
inserted into the CCA. The rats with more than 65% reduction in CBF
were included in the study. On the other hand, the rat showed a sudden
CBF reduction in both hemisphere, as a sign of hemorrhage, were ex-
cluded from the experiment.
2.3. Isolation and characterization of rat BMSCs
BMSCs were obtained from the femur and tibia bones marrow of
male Wister rats by ﬂushing method. First, the rats were deeply an-
esthetized with 10% chloral hydrate (3 mg/kg, intraperitoneal) and
decapitated. The femur and tibia bones were removed under sterile
conditions. Then, bone marrow was ﬂushed out into a 50ml falcon tube
using a syringe containing cell culture media. The cells were expanded
in a 75 cm2 cell culture ﬂask (SPL, Korea) by Dulbecco's modiﬁed
Eagle's medium (DMEM, Invitrogen, USA) that supplemented with 10%
fetal bovine serum (Invitrogen, USA) and penicillin/streptomycin
(Invitrogen, USA) and placed in an incubator (Memmert, Germany)
with 5% CO2, and 80% humidity at 37 °C temperature. After 24 h,
media and non-adherent cells were discarded and replaced with fresh
medium. Thus, BMSCs were isolated based on the capability of adherent
to plastic cell culture ﬂasks. When the conﬂuence of the cells reached
80%, they were removed by trypsin-EDTA (0.25%) and expanded in
two or more 75-cm2 ﬂasks. After three passages, cells were analyzed for
surface CD markers by ﬂowcytometry. Also, the diﬀerentiation capacity
of extracted cells was examined for conﬁrming that the cells are MSCs.
The expanded cells in passage three were subjected to a speciﬁc dif-
ferentiation media for diﬀerentiating to osteoblasts and adipocytes.
Adipogenic diﬀerentiation medium consists of low glucose DMEM
(Invitrogen, USA) supplemented with FBS and penicillin/streptomycin
(same as growth media), plus 50 μg/ml ascorbic acid- 2-phosphate,
100 nM dexamethasone and 50 μg/ml indomethacin (all from Sigma,
Germany) and Osteogenic diﬀerentiation medium consist of growth
media addition with 10mM glycerol-2-phosphate, 50 μg/ml ascorbic
acid- 2-phosphate and 100 nM dexamethasone (all from Sigma-
Aldrich). This medium was changed every 3 days. After 21 days, cells
were stained with oil red and alizarin red dyes to identify adipocytes
and osteoblasts, respectively. BMSCs were used for transplantation in
passages 3-5. A single dose of 1×106 BMSCs in 1ml saline was in-
jected into the tail vein of rats in the cell therapy group. The rats in the
control group received 1ml saline 3 h after tMCAO.
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2.4. Flow cytometry analysis
Flow cytometry analysis has been used to conﬁrm the presence or
absence of the six markers. Cells from the third passage were removed
by trypsin and cell suspensions were washed twice in PBS supplemented
with 0.5% (v/v) bovine serum albumin (BSA). Each one of antibodies
including: PE-conjugated anti‐CD34 antibody (QBEnd10; Invitrogen,
Carlsbad, CA), FITC-conjugated anti‐CD73 (SH‐3) antibody
(CiniSciences, Nanterre, France), anti‐CD44 antibody, anti‐CD45 anti-
body, anti‐CD90 antibody, and PE-conjugated anti‐CD105 (SH‐2) anti-
body (Every four of them from Abcam, Cambridge, UK), were added to
a suspension of 106 cells/ml PBS separately, and incubated for 30min
at 4 °C and protected from light. Finally, the cells were washed and
analyzed by a BD FACS Calibur ﬂow cytometer (BD Biosciences, San
Jose, CA) and results were investigated by Flowjo 7.6.1 software.
2.5. Behavioral testing
Garsia behavioral tests with minor modiﬁcations were performed 24
and 72 h after I/R as previously described [35]. Four motor tests in-
cluding spontaneous activity, walking, forepaw outstretching and
climbing and two sensory tests including body and head proprioception
were done in all of the animals by two blinded examiner. The total
scores of the tests (between 3and 18) were compared in all of animals
groups.
2.6. Cerebral infarction volume
TTC staining technique was performed to determine the infarct size.
Animals were deeply anesthetized with 10% chloral hydrate (400mg/
kg, intraperitoneal) and decapitated 72 h after I/R. Brains were re-
moved rapidly and placed in a brain matrix (Zivic Instruments, USA)
and cut into 2-mm thick coronal sections. Afterward, the brain sections
were stained by triphenyl tetrazolium chloride (TTC) 1% in PBS (W/V)
at 37° for 10min. TTC was reduced to tri-phenyl formazan in the vital
cells and its deposition causes red color but the dead cells in infarcted
tissue remain pale. Then photograph was taken from tissue sections by a
digital camera (Canon, Japan). Infarct area was assessed by image
analysis software (Image J version 1.44p, USA). Infarcted areas of all
sections were measured (mm2), data summed and then multiplied by
the distance between the sections (2 mm) in order to get the total in-
farction volume [4].
2.7. Western blot analysis
For western blot analysis, animals were sacriﬁced and their brains
were removed quickly. The tissue of ischemic penumbra was dissected
from 3 groups and lysed in 800 μl radioimmunoprecipitation assay
buﬀer (RIPA buﬀer). An equal amount of proteins were separated in
10% SDS polyacrylamide gel. After electrophoresis, the proteins on the
gel were transferred on a PVDF membrane (Roche, Germany) using a
semidry transfer apparatus and blocked with 0.2% BSA in PBS for 1 h.
Blots were probed with primary antibodies against beta-actin (ab8226,
Abcam, 1:5.000) and pJNK (sc-6254, Santa Cruz Biotechnology, 1:200)
overnight at 4 °C and subsequently incubated with secondary antibodies
conjugated with horseradish peroxidase (anti-rabbit, Abcam, 1:3.000
and anti-mouse, Santa Cruz Biotechnology, 1:4.000) for 1 h. Finally,
labeled proteins were observed with the ECL detection system (Biorad,
USA). pJNK band density was normalized to the corresponding beta-
actin band as an internal control. Protein bands were quantiﬁed using
densitometry software (Image J version 1.44, USA).
2.8. Tissue preparation and immunohistochemistry
Animals were deeply anesthetized by intraperitoneal injection of
10% chloral hydrate (mg/kg,) and perfused through the left ventricle of
the heart with saline and then ﬁxed with 10% neutral-buﬀered formalin
(NBF) (pH=7) at 72 h after reperfusion. The ﬁxed brains were care-
fully removed from the skull, sectioned into 4mm thick slices and kept
in the same ﬁxative solution for 48 h post-ﬁxation at room temperature.
After tissue processing, brains were embedded in paraﬃn, 5 μm- thick
coronal sections were prepared using a microtome (Diapath, Italy) and
placed on silane-coated slides. Then, sections were deparaﬃnized, re-
hydrated and used for immunohistochemistry, TUNEL, and Nissl
staining.
For immunohistochemistry, rehydrated sections were immersed in
an antigen retrieval solution (pre-heated 0.1 M citrate buﬀer (pH=6)
for 20min. Non-speciﬁc antibody binding was blocked with a superb-
lock solution from IHC kit (UltraTek HRP-Anti Polyvalent, Scytek, USA)
for 7min at room temperature. In the next step, slides were incubated
with primary antibodies overnight at 4 °C. The following primary an-
tibodies were used for this study: mouse monoclonal anti-pJNK (sc-
6254, Santa Cruz Biotechnology, USA) at 1:50 dilution, rabbit poly-
clonal anti-GFAP (32608, Encore, USA) at 1:1000 dilution. Then, sec-
tions were incubated in 10% H2O2 in methanol for 10min to quench
endogenous peroxidase activity. After several washing steps, sections
were treated with biotin-conjugated secondary antibodies and subse-
quently with a streptavidin-peroxidase conjugate solution for 10min.
The color reaction was visualized using diaminobenzidine (DAB). For
negative controls, slides underwent identical preparation except for the
primary antibodies.
2.9. TUNEL staining
Neuronal apoptosis was delineated by using a TUNEL kit (Roche,
Germany). TUNEL staining was performed according to the manu-
facturer’s protocol. Brieﬂy, after deparaﬃnization and rehydration,
sections were boiled in 0.1 M citrate buﬀer in a microwave (pH=6) for
10min. After rinsing with PBS, the TUNEL reaction mixture was added
on samples for 60min in a 37 °C incubator. Samples were rinsed with
PBS before they were treated with Converter-POD solution for 30min at
room temperature. DAB was used for the coloration of apoptotic cells.
2.10. Nissl staining
Initially 5 μm coronal sections were prepared for Nissl staining. The
sections were placed on the slides and paraﬃn was removed in xylene
and hydrated in ethanol. After rinsing by tap water and distilled water,
they were stained with 0.1% cresyl violet (Merck, Germany) for 3-
10min, and then slides were dried and mounted. Intact neurons con-
tained large oval nuclei while the degenerated neurons showed
shrunken and pyknotic nuclei. Counts of intact-degenerating neurons
were performed in two sections per animal. All IHC-, TUNEL- and Nissl-
stained sections were mounted and analyzed with an inverted micro-
scope (Nikon Eclipse Ti-U, Japan).
2.11. Statistical analysis
All data are presented as means ± SEM and analyzed with SPSS
software (version 22.0, USA). For comparison, the data related to CBF
repeated measurement ANOVA was used. The behavioral data were
analyzed by Kruskal–Wallis test. All of the other comparisons were
performed by one-way ANOVA and post-hoc Tukey's test. Diﬀerences
were considered to be statistically signiﬁcant if P value was<0.05.
3. Results
3.1. Isolation and characterization of BMSCs
BMSCs showed a characteristic ﬁbroblast-like cell morphology
(Fig1A). The capability of bone marrow extracted cells for diﬀerentia-
tion into osteoblasts and adipocytes were showed by culturing of the
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cells in the speciﬁc media were checked. After three weeks extra-cel-
lular calcium depositions were showed in osteogenic media by alizarin
red staining and fat vacuole were seen in adipogenic media by oil red
staining (Fig1B and C). Before transplantation, the BMSCs were ana-
lyzed for cell surface markers at passage 3. Flow cytometry analysis
conﬁrmed that BMSCs were positive for the surface antigens CD44
(97.5%), CD73 (99.8), CD 90 (98.7%), and CD105 (96.8%) which are
typically expressed in a variety of stem cells and had low expression for
hematopoietic cell surface antigens CD45 (2.62%) and CD34 (4.52%)
(Fig. 1D).
3.2. Infarct volume and behavioral scores
The infarct volume depends mainly on the blood perfusion and the
time of ischemia, but secondary factors, such as oxidative stress,
inﬂammation, and apoptosis expanded it. As expected, no infarct area
was seen in the sham group but it was clearly found in the saline group.
BMSCs signiﬁcantly decreased the infarct volume 72 h after I/R (P=
0.022).
Behavioral exam indicated that ischemic stroke signiﬁcantly de-
creased sensory and motor test scores 24 and 72 h after I/R (P= 0.001)
but BMSCs transplantation signiﬁcantly improved behavioral test 24 h
(P= 0.042) and 72 h (P= 0.016) after I/R in compared to saline
groups (Fig. 2).
3.3. MSCs therapy decreased cell death after ischemic stroke
To investigate the eﬀect of BMSCs transplantation on apoptosis,
TUNEL staining was done 72 h after I/R. There were almost no TUNEL
positive cells in the sham group and contralateral hemisphere of saline
Fig. 1. MSCs identiﬁcation: Morphology of bone marrow extracted cells after 3 passage (A). Potential diﬀerentiation of MSCs to bone and fat cells (B &C).
Flowcytometry analysis: MSCs expressed markers CD90, CD73, CD44, and CD105 and were negative for the hematopoietic cell surface molecules CD45 and CD34
(D). Sample stained with FITC Conjugated Antibodies (green), PE conjugated Antibodies (Red), Negative Control (Black).
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group animals. After tMCAO, the number of TUNEL positive cells
massively increased but treatment with BMSCs prevented this induction
of apoptosis and reduced TUNEL positive cells (P= 0.025) (Figs. 3B
and D).
3.4. MSCs transplantation reduced astroglial reactivity
GFAP is the principal intermediate ﬁlament protein of mature as-
trocytes and serves as a hallmark for reactive astrogliosis after nervous
tissue injury [36]. In the sham group, most GFAP+ astrocytes had thin
processes 72 h after surgery (Fig. 4C), while in the control tMCAO
group, GFAP+astrocytes appeared hypertrophic with thickened pro-
cesses (Figs. 4A, B). The number of reactive GFAP+astrocytes was
signiﬁcantly reduced within the boundary zone of ischemia in the
BMSCs-treated group compared with a control group 72 h after I/R
reﬂecting a reduction in ischemia-induced astrogliosis after BMSCs
treatment (p < 0.001) (Fig. 4D). Our data suggest a novel role of
BMSCs in the modulating inﬂammatory responses associated with cer-
ebral ischemia.
3.5. Morphological analysis of ischemic neuronal damage
The degree of neuronal damage was evaluated by Nissl staining. In
the sham group, neurons appeared unaﬀected and showed round and
pale-stained nuclei (Fig. 5C). In contrast, many neurons in the pe-
numbra region of the tMCAO control group showed an aberrant mor-
phology with shrunken cell bodies, chromosome condensation and
nuclear pyknosis (Fig. 5A). Treatment with BMSCs reduced the number
of degenerating neurons and signiﬁcantly preserved the intact structure
of neurons (P < 0.001) (Fig. 5B and D).
3.6. MSCs reduced JNK activation after ischemia
To conﬁrm whether the JNK pathway is activated in the brain after
focal ischemia, western blotting was performed with an antibody spe-
ciﬁc for the phosphorylated active form of JNK. Moreover, the p-JNK
positive cells were stained by immunohistochemistry and quantiﬁed in
the penumbra. I/R injury signiﬁcantly induced activation of pJNK
(Fig. 6B and D) compared to the sham group (Fig. 6F). Western blot
analysis revealed approx.30% shorter protein levels of pJNK in the
MSCs group compared to the tMCAO control group (Fig. 6A). Western
blot results were qualitatively approved by immunohistochemistry of
pJNK in control and MSCs groups (Fig. 6B–E). The administration of
BMSCs signiﬁcantly reduced the numbers of JNK-positive cells com-
pared to the saline (Figs. 6C and E, P= 0.011).
4. Discussion
In this study, we attempted to elucidate possible mechanisms un-
derlying the neuroprotective eﬀects of BMSCs in an animal model of
focal cerebral ischemia. The main observation of our study is that in-
travenously transplanted BMSCs have the capability to modulate the
local inﬂammatory response and to decrease apoptosis in the ischemic
brain most likely through inhibition of the JNK signaling cascade.
tMCAO is a well-characterized stroke model inducing ischemia-related
neurodegeneration in rodents [37] and thus, allows for studying po-
tential therapeutic compounds and related molecular mechanisms.
Besides the many site-speciﬁc pathological processes occurring im-
mediately after and with a distinct time delay in the hypoxic brain area,
neuroinﬂammation and apoptosis appear to be the major destructive
events that mainly contribute to its pathogenic progression [38]. De-
spite the development of various therapeutic measures mainly arising
from animal studies, stroke still lacks an ideal brain-suited and eﬀective
treatment [32]. MSCs have been proposed to have beneﬁcial eﬀects in
animal models of focal cerebral ischemia [18,19]. However, the me-
chanisms underlying the observed reduction of the infarct volume and
improvement of functional deﬁcits are not understood.
As expected, our ﬁndings are consistent with previous reports which
have shown that the administration of MSCs can reduce the infarct
volume and improve the functional deﬁcits after transient focal cerebral
ischemia [25,39–41]. Apoptosis plays a decisive role in mediating
neuronal death after cerebral ischemia [42] and the penumbra region is
particularly vulnerable to apoptosis in the early follow-up period
(hours) after the onset of reduced blood supply. Therefore, the
Fig. 2. Ischemic stroke signiﬁcantly decreased behavioral scores
(***P < 0.001). BMSCs improved the neurological deﬁcits and behavioral
scores signiﬁcantly increased 24 h (*P= 0.042) and 72 h (# P= 0.015) after I/
R in compared to the saline group.
Fig. 3. Infarct Volume: TTC-stained brain slices showed a massive infarct area (white zone) 72 h after I/R. Treatment with BMSCs reduced the infarct volume.
Quantitative analysis of the cerebral infarct volume indicated a signiﬁcant decrease by MSCs 72 h after I/R (*P= 0.022). St: striatum, Cx: cortex.
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attenuation of apoptosis in this brain region is one of the prime goals of
therapeutic interventions [43]. Previous studies have demonstrated a
protective role of MSCs transplantation against neuronal apoptosis in
both permanent and transient focal ischemia models [44,45]. Here, we
additionally report that BMSCs protect neurons against an ischemic
insult. Evidence of this protection is that BMSCs notably increased the
neuronal surviving- and decreased apoptosis rate. Isele et al. showed
that BMSCs secrete a combination of multiple growth factors and cy-
tokines that activate endogenous survival signaling pathways such as
PI3K/Akt and the MAPK/ERK1/2 cascade [46]. This is supported by
ﬁndings from another disease and animal model where MSCs provoke
anti-apoptotic eﬀects after myocardial infarction. This protective eﬀect
Fig. 4. Eﬀects of MSCs on apoptosis: TUNEL staining showed an increased number of apoptotic cells in the striatum in the saline group. BMSCs signiﬁcantly
decreased the number of TUNEL-positive cells. (*P= 0.025).
Fig. 5. MSCs therapy and astrocyte. Astrocytes
are visualized by anti-GFAP staining. Ischemia
signiﬁcantly increased the number of reactive
GFAP-positive cells in the striatum at 72 h after
I/R in compared to the sham group (A, C)
(***P < 0.001). BMSCs signiﬁcantly reduced
the number of GFAP-positive cells (**P=
0.002). The comparison of GFAP- positive cells
in the ischemic penumbra was done as a
number of cells/mm2 (B, D).
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appeared to be mediated through the stimulation of mitogen-activated
protein kinases pathways, including JNK, extracellular signal-regulated
kinase (ERK) and p38 [47,48].
The astrocytes were activated by ischemia and converted to reactive
astrocytes which have been identiﬁed to play a role in neurogenesis.
[49]. Astroglial reactivity in the peri-infarct region is also an interesting
and potential goal for therapeutic interventions [40]. In this study, we
indicated a decreased astroglial reactivity in the peri-infarct zone of
BMSCs-treated animals compared to the control group. These results
are in line with a previous report by Pavlichenko et al [50] who
Fig. 6. Eﬀects of BMSCs on JNK activation. (A) Western Blots result indicated a decreased expression of p-JNK in the MSCs group compared with the saline group
72 h after I/R. Immunohistochemistry results showed a lower expression of p-JNK in the penumbra region of the striatum in BMSCs treated group (C) compared to the
saline group (B) 72 h after I/R (*P=0.011) (D–E). CC: corpus callosum.
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observed the widest glial scar in the control group and moderate glial
scar in the MSCs therapy group in a rat stroke model. Another possible
mechanism has been proposed by Huang et al. who showed that
paracrine factors secreted by MSCs can promote astrocyte survival and
down-regulate GFAP expression via the suppression of p38 MAPK and
JNK [51]. Therefore, the anti-inﬂammatory properties of BMSCs might
be a major component of its beneﬁcial eﬀects against I/R injury [52].
To further pinpoint putative molecular mechanisms which are in-
volved in BMSCs-dependent neuroprotection, we investigated the JNK
signaling pathway that plays a major role in ischemia-induced neu-
roinﬂammation and cell death [33]. A previous study showed the role
of JNK signaling pathways in apoptosis of Jurkat T cell, which was
induced by adipogenic MSCs [53]. Although the MSCs im-
munomodulatory eﬀects are well known, various molecular mechan-
isms are mentioned that need further investigation.
In this study, the administration of MSCs clearly inhibited the in-
crease in pJNK-expressing cells compared to tMCAO. The JNK has been
demonstrated as a crucial mediator in triggering neuronal apoptosis
following ischemia [30,54] and phosphorylation of the downstream
molecules like c-Jun involves in its pro-apoptotic function [55]. Acti-
vation of the JNK signaling results to cell death via not only intrinsic/
extrinsic apoptotic pathways, but also pro-inﬂammatory cytokine pro-
duction [30]. The JNK phosphorylation also appears to be linked to
astrocyte function/dysfunction in the penumbra after ischemia [56].
Therefore, The JNK activity seems to be important for both the immune
response and apoptosis. Thus, the blockade and attenuation of JNK
activation could be one pivotal mechanism against cerebral ischemia-
induced brain damage [31,57] and could prevent astroglial reactivity,
neuronal apoptosis [51,58].
In conclusion, the present data support the view that the adminis-
tration of BMSCs in focal brain ischemia-induced animals could be
neuroprotective. Taken together, our results suggested that anti-in-
ﬂammatory and anti-apoptotic properties of MSCs are considerably
contributed to its protective eﬀects via targeting JNK pathway. These
ﬁndings revealed, the JNK pathway may be introduced as an important
molecular mechanism in the ischemic stroke injury.
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